{"authors": [["Charoensri", "Suranut", "S", "Division of Endocrinology and MetabolismDepartment of MedicineFaculty of Medicine Ramathibodi HospitalMahidol UniversityBangkok10400Thailand."], ["Sriphrapradang", "Chutintorn", "C", "Division of Endocrinology and MetabolismDepartment of MedicineFaculty of Medicine Ramathibodi HospitalMahidol UniversityBangkok10400Thailand."], ["Nimitphong", "Hataikarn", "H", "Division of Endocrinology and MetabolismDepartment of MedicineFaculty of Medicine Ramathibodi HospitalMahidol UniversityBangkok10400Thailand."]], "date": "2017-09-08", "id": "29026577", "text": "High-dose intravenous thyroxine (T4) is the preferable treatment for myxedema coma. We describe the clinical course of a 69-year-old man who presented with myxedema coma and received oral levothyroxine (LT4) therapy (1\u00a0mg) in a split dose. This suggests split high-dose oral LT4 as a therapeutic option in myxedema coma.", "doi": "10.1002/ccr3.1131", "title": "Split high-dose oral levothyroxine treatment as a successful therapy option in myxedema coma.", "journal": ["Clinical case reports", "Clin Case Rep"]}